NCT05774093 Evaluation of COVID-19 Immune Barrier and Reinfection Risk
| NCT ID | NCT05774093 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | COVID-19 Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-03-06 |
| Primary Completion | 2024-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-03-06 with a primary completion date of 2024-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the protective effect of immune barrier on secondary infection after COVID-19 (coronavirus disease 2019) vaccination or COVID-19 virus Omicron B A. 5.2 strain infection by dynamically monitoring the COVID-19 antibody titer, cellular immune function and the occurrence of secondary infection of healthy participants, mainly medical staff in our hospital, to understand the cross protective effect of COVID-19 antibody on different variants of Omicron, and explore the best time to use COVID-19 vaccine to strengthen immunity after Omicron mutant infection.
Eligibility Criteria
Inclusion Criteria: 1. No age limit, no gender limit; 2. Medical staff, administrative and logistics staff who work in the Third Affiliated Hospital of Sun Yat-Sen University or other participants who can cooperate with the follow-up for 48 weeks; 3. The participants need to be sure whether they have ever been infected with COVID-19, and need to be clearly remember the time when they first infected with COVID-19. Exclusion Criteria: 1. Have the following serious respiratory diseases: such as asthma, bronchiectasis, chronic obstructive pulmonary disease, pulmonary interstitial disease, tuberculosis and other respiratory diseases that may interfere with symptom observation; 2. Those with other serious diseases or disease history that affect immune function, including but not limited to uncontrolled and unresectable malignant tumors,hematological diseases, cachexia, active bleeding, severe malnutrition, mental diseases, autoimmune diseases, HIV, etc. 3. Those who have long-term assignment plans and cannot return to the hospital regularly for follow-up.
Frequently Asked Questions
Who can join the NCT05774093 clinical trial?
This trial is open to participants of all sexes, studying COVID-19 Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05774093 currently recruiting?
Yes, NCT05774093 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sun Yat-sen University to inquire about joining.
Where is the NCT05774093 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05774093 clinical trial?
NCT05774093 is sponsored by Sun Yat-sen University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.